First Mature Estimation of Median OS for Selpercatinib in Patients with RET Fusion-Positive NSCLC By Ogkologos - March 12, 2025 412 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from final efficacy and safety analyses from the LIBRETTO-001 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... February 16, 2023 Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations February 8, 2023 A peek behind the scenes: Just how are our funding decisions... July 6, 2022 A Cancer Revolution comes to Manchester: Patrick’s review November 24, 2021 Load more HOT NEWS Targeted Therapy for Claudin-18.2 and Combined PD-1 and TIGIT Immunotherapy for... Contraception and cancer – a look behind the headlines Real-World Increase in Biomarker Testing in Lung Cancer Patients, Registry Study... Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia
